Drugs / ORG101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05131373 | Sep 2021 → Nov 2023 | acne | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORG101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05131373 ↗ |
| Known as | ORI-A-ce001 | “The present randomized, placebo-controlled, dose escalation, Phase 1 trial (ORI-101-PAC) is intended to investigate the safety, tolerability and immunogenicity of an acne...” NCT05131373 ↗ |
| Modality | Vaccine | “an acne vulgaris vaccine (ORI-A-ce001)” NCT05131373 ↗ |
| Route | Intramuscular | “4 single i.m. injections given in monthly intervals” NCT05131373 ↗ |